Berger et al. investigated the accumulation of nilotinib in CML CD34+ cells and polymorphonuclear cells and found that nilotinib uptake in primary C-PCML cells was dependent on the heterogeneous expression of membrane transporters among different cell types within the CML population [37]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.